Patient Perspectives in Mantle Cell Lymphoma Clinical Research
NCT06049472 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 500
Last updated 2023-09-22
Summary
Clinical studies with a distinct emphasis on mantle cell lymphoma play a pivotal role in evaluating the safety and effectiveness of novel treatments for this disease. These trials are instrumental in ascertaining whether new medications surpass conventional therapies, providing substantial evidence to endorse their broad utilization.
This particular study stands out as it centers on the firsthand experiences of individuals battling mantle cell lymphoma who are actively engaged in a clinical trial featuring medicinal interventions. The primary objective is to meticulously scrutinize trial completion rates and voluntary withdrawals within this patient group.
Conditions
Sponsors & Collaborators
-
Power Life Sciences Inc.
lead INDUSTRY
Principal Investigators
-
Michael B Gill · Power Life Sciences Inc.
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-10-31
- Primary Completion
- 2025-10-31
- Completion
- 2026-10-31
Countries
- United States
Study Locations
More Related Trials
-
Assessing the Experience of Patients Undergoing Follicular Lymphoma Clinical Research
NCT06049485 ·Status: NOT_YET_RECRUITING
-
Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma
NCT02242097 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Phase III, Multicentre, Randomised Study of Fludarabine/Cyclophosphamide Combination With or Without Rituximab in Patients With Untreated Mantle Cell Lymphoma
NCT00641095 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Prospective Trial on Immunochemotherapy Plus Autologous Stem Cell Transplantation (SCT) and Allogenic SCT in Primary Mantle-Cell-Lymphoma
NCT00946374 ·Status: UNKNOWN ·Phase: PHASE2
-
Sequential Chemo-Radioimmunotherapy Followed by Autologous Transplantation for Patients With Untreated Advanced Stage Mantle Cell Lymphoma
NCT01484093 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL
NCT00490529 ·Status: COMPLETED ·Phase: PHASE2
-
Combination Chemotherapy With or Without Rituximab in Treating Patients With Mantle Cell Lymphoma
NCT00053092 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Efficacy of Lenalidomide as Maintenance Therapy After Completion of First-line Combination Chemotherapy in Patients With Mantle Cell Lymphoma (MCL).
NCT01021423 ·Status: TERMINATED ·Phase: PHASE3
-
Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma
NCT02633137 ·Status: COMPLETED ·Phase: PHASE2
-
Zanubrutinib in the Treatment of Recurrent Refractory Mantle Cell Lymphoma
NCT05486013 ·Status: RECRUITING
-
Mantel Cell Lymphoma Efficacy of Rituximab Maintenance
NCT00921414 ·Status: COMPLETED ·Phase: PHASE3
-
Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma
NCT02427620 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Prospective, Single-Center Study Evaluating the Efficacy and Safety of Glofitamab Combined With Orelabrutinib and Bortezomib in Patients With High-Risk Mantle Cell Lymphoma
NCT06656221 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Combination Chemotherapy and Rituximab in Treating Patients With Untreated Mantle Cell Lymphoma
NCT00433537 ·Status: COMPLETED ·Phase: PHASE2
-
Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant
NCT01437709 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of the Kinetics of Lymphoid Cells in Patients With Monoclonal B-cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), Mantle Cell Lymphoma (MCL) and Healthy Volunteers
NCT01117142 ·Status: COMPLETED
-
Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL
NCT00209209 ·Status: UNKNOWN ·Phase: PHASE3
-
A Single-arm, Single-center, Open-label Phase II Study of Zanubrutinib Combined With R-CHOP/R-DHAP in Newly Diagnosed Mantle CellLymphoma Patients
NCT06255704 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
S0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
NCT00376961 ·Status: COMPLETED ·Phase: PHASE2
-
Ketogenic Diet in Patients With Untreated Low Tumor Burden Mantle Cell Lymphoma
NCT04231734 ·Status: WITHDRAWN ·Phase: NA
-
S0213 Chemotherapy Plus Rituximab in Treating Patients With Mantle Cell Lymphoma
NCT00041132 ·Status: COMPLETED ·Phase: PHASE2
-
Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma
NCT06675123 ·Status: RECRUITING ·Phase: PHASE1
-
Ibrutinib Combined With Bendamustine and Rituximab in Newly Diagnosed Mantle Cell Lymphoma Patients Who Aged > 65 Years
NCT05406154 ·Status: UNKNOWN
-
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
NCT06084936 ·Status: RECRUITING ·Phase: PHASE3
-
Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma
NCT03282396 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2